Suzette Kox, MPharm, Secretary General of the International Generic and Biosimilar Medicines Association (IGBA), discusses the FDA’s recent guidance on the naming of biosimilars, biologics, and interchangeable products.
Tanscript
The updated guidance is inconsistent and it will create confusion and therefore create a safety problem. I think it’s still a possibility or hope that FDA will eventually park completely this guidance document and not apply suffixes anymore, and why we think that is because they have to take into account a number of realities. And what are those realitizes? Well, first is that FDA’s the only jurisdiction in the world which has used or applies suffixes—meaningless, unmemorable suffixes—to biosimilars and new biologics. And we believe that, because pharmacovigilance is a global activity and not only a national activity, that FDA should align with the highly regulated markets around the world, so that’s one important point of reality.
The second one, and it’s a very interesting one, is the fact that, I think it's in publication or an article of 2013, it was mentioned that we had 77 biologics on the US market which shared 23 nonpropritary names. In other words, because FDA does not apply the suffix to those products, it confirms that they don't consider that there is a safety issue or pharmacovigilance issue with biologics sharing the same nonproprietary name. And we share that with the FDA.
The other very important point is what happens today with the [adverse drug reaction, ADR] reports. When you go on the dashboard of the FDA website where they list the adverse events, somebody made the calculation, and looked every single biosimilar report, and found out that all ADRs which were linked to biosimilars have been identified to 99.1% with the brand name, so pharmacovigilance is assured. So, I think that's a very compelling point, and then maybe another important point is that I think FDA is working on a pilot project for track-and-trace, which will identify the products down to the batch number, and that’s the ultimate goal—that we identify down to the batch number—and a suffix can never do that.
From a personal perspective, because for IGBA, we have not yet finalized our comments to the FDA naming guidance, and we will do that, I think if FDA does not stick to what they have proposed now, I think they must apply the suffix also to all reference products for which biosimilars are approved. I even go further, and as I said, this is my personal opinion right now, and we’ll see if that will end up in our comment position, is that even for biologics for which which do not have a suffix now, but which undergo a manufacturing change and for which companies need to provide data to prove that safety and efficacy is not altered, that these products also need to retroactively have a suffix.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.